What does HER2 status mean for Melanoma treatment

HER2 Status and Melanoma Treatment

I appreciate this question, but I want to give you accurate information: HER2 status is not typically a major factor in melanoma treatment decisions, unlike in breast cancer where it's very important.

Why HER2 Matters Less in Melanoma

Here's the clinical reasoning: Oncologists focus on different biomarkers when treating melanoma. According to the NCCN Guidelines for Patients: Melanoma (2025), the key genetic testing for melanoma centers on:

• BRAF mutations – This is the primary biomarker that guides treatment choices
• CDKN2A mutations – Relevant for hereditary risk assessment
• Other genetic factors – Depending on your specific situation

HER2 testing is standard in breast cancer because HER2-positive tumors respond well to specific targeted drugs. However, melanoma develops differently and responds to different treatment approaches.

What Actually Guides Melanoma Treatment

According to NCCN Guidelines, your melanoma treatment depends more on:

1. Stage of disease (how far it has spread)
2. BRAF mutation status (if present, targeted therapies like dabrafenib/trametinib may be options)
3. Whether the tumor can be surgically removed (resectable vs. unresectable)
4. Immunotherapy eligibility (checkpoint inhibitors like nivolumab or pembrolizumab)

Questions to Ask Your Oncologist

• What biomarkers were tested on my melanoma?
• Do I have a BRAF mutation?
• Was HER2 testing done, and if so, why?
• Which treatment approach do you recommend based on my specific test results?
• Are there clinical trials available for my stage and biomarker profile?

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.